Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's "Brain Hemorrhage Pipeline Insight 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Brain Hemorrhage pipeline landscape. It covers the Brain Hemorrhage pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Brain Hemorrhage pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Brain Hemorrhage Pipeline Report*DelveInsight's Brain Hemorrhage pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Brain Hemorrhage treatment. *The leading companies working in the Brain Hemorrhage Market include Jiangsu Simcere Pharmaceutical Co., Ltd., AegisCN, NeurOp, Inc., Capricor Therapeutics, aptaTargets, Novartis Pharmaceuticals, Evgen Pharma, BIT pharma, Acasti Pharma Inc., and others. *Promising Brain Hemorrhage Pipeline Therapies in the various stages of development include rt-PA, cHS, SANGUINATE, Clazosentan, IRRAflow, NXY-059, Esomezol Cap, and others. *November 2023: Acasti Pharma Inc. announced a study of Phase 3 clinical trials for GTX-104 and Nimotop 30 MG Oral Capsule. The purpose of this study is to deliver nimodipine via IV directly into the bloodstream and to determine if this is as safe and tolerable as oral nimodipine capsules. Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared With Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial. *October 2023: Bioxodes S.A announced a study of Phase 2 clinical trials for Ir-CPI. The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage. A Phase IIa, Randomized, Open-label, Proof-of-Concept Study to Evaluate Safety, Tolerability and Efficacy of Ir-CPI in Patients With Spontaneous Intracerebral Haemorrhage. *September 2023: Joseph Broderick MD announced a study of Phase 3 clinical trials for Recombinant Activated Factor VII (rFVIIa). The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.

Request a sample and discover the recent advances in Brain Hemorrhage Treatment Drugs @ Brain Hemorrhage Pipeline Report

In the Brain Hemorrhage pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brain Hemorrhage collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Brain Hemorrhage Overview

A brain hemorrhage refers to bleeding in the brain. This medical condition is also known as a brain bleed or an intracranial hemorrhage. It is a medical emergency that requires immediate treatment. The skull surrounds the brain, and any leaking blood from a hemorrhage can cause compression and damage to the brain tissues.

Find out more about Brain Hemorrhage Therapeutics Assessment @ Brain Hemorrhage Preclinical and Discovery Stage Products

Brain Hemorrhage Emerging Drugs Profile*CN 105: AegisCN *NP10679: NeurOp, Inc.

Brain Hemorrhage Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the Brain Hemorrhage therapies. The Brain Hemorrhage companies which have their Brain Hemorrhage drug candidates in the most advanced stage, i.e. phase II include, AegisCN.

DelveInsight's Brain Hemorrhage pipeline report covers around 10+ products under different phases of clinical development like*Late stage products (Phase III) *Mid-stage products (Phase II) *Early-stage product (Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates

Brain Hemorrhage pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as*Inhalation *Inhalation/Intravenous/Oral *Intranasal *Intravenous *Intravenous/ Subcutaneous *NA *Oral *Oral/intranasal/subcutaneous *Parenteral *Subcutaneous

Brain Hemorrhage Pipeline Products have been categorized under various Molecule types such as*Antibody *Antisense oligonucleotides *Immunotherapy *Monoclonal antibody *Peptides *Protein *Recombinant protein *Small molecule *Stem Cell *Vaccine

Learn more about the emerging Brain Hemorrhage Pipeline Therapies @ Brain Hemorrhage Clinical Trials Assessment

Scope of the Brain Hemorrhage Pipeline Report*Coverage- Global *Brain Hemorrhage Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination *Brain Hemorrhage Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III *Brain Hemorrhage Companies- Jiangsu Simcere Pharmaceutical Co., Ltd., AegisCN, NeurOp, Inc., Capricor Therapeutics, aptaTargets, Novartis Pharmaceuticals, Evgen Pharma, BIT pharma, Acasti Pharma Inc., and others. *Brain Hemorrhage Pipeline Therapies in the various stages of development include rt-PA, cHS, SANGUINATE, Clazosentan, IRRAflow, NXY-059, Esomezol Cap, and others.

Dive deep into rich insights for new drugs for Brain Hemorrhage Treatment, Visit @ Brain Hemorrhage Market Drivers and Barriers, and Future Perspective

Table of Content*Introduction *Executive Summary *Brain Hemorrhage: Overview *Pipeline Therapeutics *Therapeutic Assessment *Brain Hemorrhage - DelveInsight's Analytical Perspective *Late Stage Products (Phase III) *Drug name: Company name *Drug profiles in the detailed report..... *Mid Stage Products (Phase II) *CN 105: AegisCN *Drug profiles in the detailed report..... *Early Stage Products (Phase I) *NP10679: NeurOp, Inc. *Drug profiles in the detailed report..... *Preclinical and Discovery Stage Products *Drug name: Company name *Drug profiles in the detailed report..... *Inactive Products *Brain Hemorrhage Key Companies *Brain Hemorrhage Key Products *Brain Hemorrhage- Unmet Needs *Brain Hemorrhage- Market Drivers and Barriers *Brain Hemorrhage- Future Perspectives and Conclusion *Brain Hemorrhage Analyst Views *Brain Hemorrhage Key Companies *Appendix

For further information on the Brain Hemorrhage Pipeline therapeutics, reach out to Brain Hemorrhage Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Email: [e-mail]

Phone: [phone]

Address:304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/report-store/brain-hemorrhage-market

Source: www.abnewswire.com

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE